Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P72S | ISIN: NL0015285941 | Ticker-Symbol: 4A3
Tradegate
23.10.25 | 17:38
8,700 Euro
-0,40 % -0,035
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMATICS NV Chart 1 Jahr
5-Tage-Chart
IMMATICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
8,8108,92018:07
8,8108,92018:07

Aktuelle News zur IMMATICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoImmatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium319One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit...
► Artikel lesen
IMMATICS Aktie jetzt für 0€ handeln
01.10.Immatics appoints industry veteran as CFO31
01.10.Immatics Appoints Venkat Ramanan As CFO5
01.10.Immatics N.V. - 6-K, Report of foreign issuer4
01.10.Immatics Appoints Venkat Ramanan as Chief Financial Officer355Houston, Texas and Tuebingen, Germany, October 1, 2025 - Immatics N.V.as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedInand Instagram.Forward-Looking...
► Artikel lesen
18.08.Mizuho reiterates Outperform rating on Immatics stock following Q2 results65
13.08.Immatics GAAP EPS of -€0.58, revenue of €4.74M14
13.08.Immatics Announces Second Quarter 2025 Financial Results and Business Update621Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated...
► Artikel lesen
13.08.Immatics N.V. - 6-K, Report of foreign issuer6
18.06.Immatics N.V. - 6-K, Report of foreign issuer11
02.06.Immatics rises on data from early stage cell therapy trial30
02.06.Cantor Fitzgerald reiterates overweight rating on Immatics stock27
02.06.Immatics N.V. - 6-K, Report of foreign issuer8
31.05.Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma899Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing...
► Artikel lesen
28.05.Deutsche Bank setzt 10 US-Dollar Kursziel für Immatics-Aktie mit Kaufempfehlung58
28.05.Deutsche Bank sets $10 target for Immatics stock on Buy rating11
13.05.Immatics GAAP EPS of -€0.3326
13.05.Immatics Announces First Quarter 2025 Financial Results and Business Update619IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b...
► Artikel lesen
13.05.Immatics N.V. - 6-K, Report of foreign issuer5
23.04.Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting581Houston, Texas and Tuebingen, Germany, April 23, 2025 - Immatics N.V.(NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5